Displaying drugs 14276 - 14300 of 14880 in total
4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE
Experimental
N-oxo-2-(phenylsulfonylamino)ethanamide
Experimental
2-(3-NITROPHENYL)ACETIC ACID
Experimental
N-(3-AMINOPROPYL)-2-NITROBENZENAMINE
Experimental
123I-iodometomidate
123I-iodometomidate is under investigation in clinical trial NCT00454103 (Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy).
Investigational
FT-1101
FT-1101 is a novel Bromodomain and Extra-Terminal motif (BET) inhibitor. FT-1101 is under investigation in clinical trial NCT02543879 (Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies).
Investigational
Matched Description: … FT-1101 is a novel Bromodomain and Extra-Terminal motif (BET) inhibitor. …
4-[(METHYLSULFONYL)AMINO]BENZOIC ACID
Experimental
4-(2-amino-1,3-thiazol-4-yl)phenol
Experimental
A-620223
Experimental
Sulfabromomethazine
Vet approved
SC-236
SC-236 is a potent, selective, orally active inhibitor of cyclooxygenase-2 (COX-2) that has been studied in cancer therapy , lower back pain , and inflammation , , , .
Experimental
Investigational
Matched Description: … cyclooxygenase-2 (COX-2) [L2964] that has been studied in cancer therapy [A33375], lower back pain [A33376], and …
TOP-1288
TOP-1288 is under investigation in clinical trial NCT02888379 (Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative Colitis).
Investigational
Matched Description: … under investigation in clinical trial NCT02888379 (Phase 2a Study to Evaluate the Safety/Tolerability and …
Trelagliptin
Trelagliptin is under investigation in clinical trial NCT03555591 (Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus").
Investigational
XL765
XL765 is an orally available small molecule that has been shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR). It is being developed by Exelixis, Inc.
Investigational
Matched Description: … shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and …
Displaying drugs 14276 - 14300 of 14880 in total